On this page
The hours after a heart attack kill heart muscle that does not grow back, and the scar left behind determines whether someone develops heart failure. Stem cell therapy after a heart attack has been tested in more randomised trials than almost any application in regenerative medicine, including a recent phase 3 trial — and the honest summary is that the effect, if present, is small.
The phase 3 trial
Intracoronary infusion of cells has been tested in a phase 3 randomised clinical trial aimed at preventing heart failure after a heart attack — Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).
Phase 3 is where treatments are confirmed or abandoned. Reaching it means earlier phases were promising enough to justify the expense, which in itself distinguishes this indication from almost everything else on this site.
The endpoint — prevention of heart failure — is a clinically meaningful one rather than an imaging number, and that matters.
This page is graded higher than its neighbours for those reasons, and the grading is about evidence quality rather than about how well the treatment works.
Timing is the whole thing
The trials treat patients within days of the infarct, during the window when the heart is remodelling and scar is forming.
That window closes. A treatment given months or years later is addressing established scar, which is a different problem, and no trial supports treating it that way.
This has an obvious consequence for medical tourism: nobody flies to another country days after a heart attack. The patients who present to clinics abroad are, by definition, outside the window the trials tested.
Anyone offering this treatment years after an infarct on the strength of these trials is offering something the trials did not study.
Why the numbers shrank
The first wave of trials in the 2000s reported ejection fraction improvements that generated real excitement and a great deal of investment.
Subsequent larger and better-controlled trials found smaller effects, and meta-analyses of the field have been notably cautious. Some early results were later found to rest on data problems, which prompted considerable soul-searching within cardiology.
An intracoronary injection trial included a sub-study of the microcirculation — Intracoronary stem-cell injection after myocardial infarction: microcirculation sub-study — and earlier work examined coronary remodelling over time — Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction.
The field’s willingness to publish deflating results is a mark in its favour, and it is why this literature can be trusted in a way that clinic marketing cannot.
What actually saves heart muscle
Opening the blocked artery quickly. Primary angioplasty within the first hours saves more muscle than anything else available, and every minute counts.
After that, the drug regimen — antiplatelets, statins, beta blockers, renin-angiotensin blockade and the newer heart failure agents where indicated — has large randomised evidence behind it.
Cardiac rehabilitation improves survival and function and is consistently under-used. It is free or cheap in most health systems and requires only attendance.
Cell therapy is being studied as an addition to all of that, never as a replacement for it.
What the heart can and cannot do
Heart muscle cells divide at an extremely low rate in adults. Muscle lost to an infarct is replaced by scar, and scar does not contract.
The surviving muscle compensates by thickening and by working harder, and over time that compensation itself becomes harmful — the process called adverse remodelling that leads to heart failure.
Treatment after a heart attack is largely aimed at limiting that remodelling. Cell therapy is being tested within that frame, not as a means of replacing the lost muscle.
The phrase “regrow your heart” describes no published trial. Ischaemic heart disease covers the mechanism question in more detail.
Delivery, and what is sold instead
Trials use intracoronary infusion through a catheter, or direct injection into heart muscle. Both require a cardiac catheterisation laboratory and an interventional cardiologist.
A phase I study has examined a cell spray applied during surgery in ischaemic cardiomyopathy — Safety and therapeutic potential of allogeneic adipose-derived stem cell spray transplantation in ischemic cardiomyopathy: a phase I clinical trial.
An intravenous infusion in a day clinic is a different intervention. It is what is most commonly available commercially, and it is not what the phase 3 evidence describes.
Mesenchymal stem cell therapy covers what is known about where infused cells travel.
What a trial would have to show
Fewer hospital admissions for heart failure. Fewer deaths. Better exercise capacity that persists at a year rather than at six weeks.
Those endpoints are expensive to measure, which is why so much of the early literature reported ejection fraction instead. Imaging is cheap and available; following a thousand patients for two years is not.
When a trial does report hard endpoints, it deserves attention regardless of whether the result is favourable. A negative trial on a hard endpoint is worth more than a positive one on a soft measure.
Risks
Catheter-based delivery carries the risks of cardiac catheterisation, which are well characterised and manageable in the right setting.
Arrhythmia has been a monitored concern with intramyocardial delivery of some cell types.
In a patient with recent infarction, any procedure carries elevated risk. That argues for doing it inside a trial with monitoring rather than in a clinic.
Documented adverse events covers the wider safety picture.
Questions worth asking
- How long ago was my heart attack, and does the trial window still apply?
- Is delivery intracoronary, intramyocardial or intravenous?
- What is my current ejection fraction, and who measured it?
- Have I completed cardiac rehabilitation and been optimised on medication?
- Is there a trial I could enter rather than paying for treatment?
The limits of current evidence covers what remains unknown across this field.
Frequently asked questions
Why is this graded higher than most pages here?
Because phase 3 randomised evidence exists and the wider trial literature is large. That is about evidence quality, not about how well it works.
Can I have this years after my heart attack?
The trials treated patients within days, during the remodelling window. Nothing supports treating established scar the same way.
Will it regrow the damaged muscle?
No published trial describes that. Lost muscle becomes scar, and treatment is aimed at limiting the remodelling that follows.
Why were early results better?
Larger, better-controlled trials found smaller effects, and some early results were later found to rest on data problems.
Is an IV drip equivalent?
No. The trials delivered cells into the coronary arteries or the heart muscle, in a catheterisation laboratory.
What helps most after a heart attack?
Opening the artery fast, then the drug regimen and cardiac rehabilitation. All have large randomised evidence and rehabilitation is consistently under-used.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.